---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-24-000066"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:39:15.741289+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash

## Summary
- Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.
- Consideration of ~$300M in cash; expected closing by end of 2024.
- Innovalve to join TMTT product group; initial investment made in 2017.
- Edwards' SAPIEN M3 TMVR system on track for European approval by end of 2025.
- Acquisition aims to expand treatable mitral valve population with combined platform.

## SEC filing metadata
- accession: 0001099800-24-000066
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000066/0001099800-24-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000066/ew-20240715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-24-000066
- JSON: https://secwatch.observer/filing/0001099800-24-000066.json
- Plain text: https://secwatch.observer/filing/0001099800-24-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.